Allergic Conjunctivitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Allergic Conjunctivitis – Pipeline Review, H2 2017’, provides an overview of the Allergic Conjunctivitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis

The report reviews pipeline therapeutics for Allergic Conjunctivitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Allergic Conjunctivitis therapeutics and enlists all their major and minor projects

The report assesses Allergic Conjunctivitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Allergic Conjunctivitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Allergic Conjunctivitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Accolade Pharmaceuticals LLC

Aldeyra Therapeutics Inc

AlleCures Inc

Allergan Plc

Clevexel Pharma SAS

Griffin Discoveries BV

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Portola Pharmaceuticals Inc

Re-Pharm Ltd

Realm Therapeutics Plc

Sylentis SAU

Xencor Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Allergic Conjunctivitis - Overview

Allergic Conjunctivitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Allergic Conjunctivitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Allergic Conjunctivitis - Companies Involved in Therapeutics Development

Accolade Pharmaceuticals LLC

Aldeyra Therapeutics Inc

AlleCures Inc

Allergan Plc

Clevexel Pharma SAS

Griffin Discoveries BV

Ocular Therapeutix Inc

Ohr Pharmaceutical Inc

Portola Pharmaceuticals Inc

Re-Pharm Ltd

Realm Therapeutics Plc

Sylentis SAU

Xencor Inc

Allergic Conjunctivitis - Drug Profiles

ADX-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGN-229666 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergen for Allergic Conjunctivitis and Allergic Rhinitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPC-888 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexamethasone acetate SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Allergic Conjunctivitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-134 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GD-136 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRT-2761 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-0217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYL-116011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XmAb-7195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Zafi-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Allergic Conjunctivitis - Dormant Projects

Allergic Conjunctivitis - Discontinued Products

Allergic Conjunctivitis - Product Development Milestones

Featured News & Press Releases

Oct 16, 2017: Realm Therapeutics to Present Update on Drug Development Program PR013 at 2017 BIO Investor Forum

Oct 10, 2017: Aldeyra Therapeutics Announces New Data on ADX-102 at 2017 Research & Development Day

Sep 27, 2017: Aldeyra Therapeutics Announces 2017 Research and Development Day

Sep 21, 2017: Realm Therapeutics Provides Clinical Development Update on PR013

Sep 11, 2017: Realm Therapeutics - FDA Permits PR013 to Proceed to Phase II Trial

Sep 07, 2017: Realm Therapeutics to present update on PR013 at the Rodman & Renshaw 19th Annual Global Investment Conference

Aug 02, 2017: Realm Therapeutics Submits Investigational New Drug Application for PR013 for Allergic Conjunctivitis

Jul 06, 2017: Realm Therapeutics - Presentation at World Congress on Inflammation

Jun 14, 2017: Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing

Jun 14, 2017: Realm Therapeutics to present on PR013 at the 2017 Marcum Microcap Conference

Jun 13, 2017: Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial

Apr 18, 2017: Aldeyra Therapeutics Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial

Feb 07, 2017: Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial

Jan 05, 2017: Realm Therapeutics to provide update on PR013 at the 2017 Dermatology Summit and Biotech Showcase

Dec 05, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 for the Treatment of Allergic Conjunctivitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Allergic Conjunctivitis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Allergic Conjunctivitis – Pipeline by Accolade Pharmaceuticals LLC, H2 2017

Allergic Conjunctivitis – Pipeline by Aldeyra Therapeutics Inc, H2 2017

Allergic Conjunctivitis – Pipeline by AlleCures Inc, H2 2017

Allergic Conjunctivitis – Pipeline by Allergan Plc, H2 2017

Allergic Conjunctivitis – Pipeline by Clevexel Pharma SAS, H2 2017

Allergic Conjunctivitis – Pipeline by Griffin Discoveries BV, H2 2017

Allergic Conjunctivitis – Pipeline by Ocular Therapeutix Inc, H2 2017

Allergic Conjunctivitis – Pipeline by Ohr Pharmaceutical Inc, H2 2017

Allergic Conjunctivitis – Pipeline by Portola Pharmaceuticals Inc, H2 2017

Allergic Conjunctivitis – Pipeline by Re-Pharm Ltd, H2 2017

Allergic Conjunctivitis – Pipeline by Realm Therapeutics Plc, H2 2017

Allergic Conjunctivitis – Pipeline by Sylentis SAU, H2 2017

Allergic Conjunctivitis – Pipeline by Xencor Inc, H2 2017

Allergic Conjunctivitis – Dormant Projects, H2 2017

Allergic Conjunctivitis – Dormant Projects, H2 2017 (Contd..1), H2 2017

Allergic Conjunctivitis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Allergic Conjunctivitis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports